Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-IL13 antibody variable domain is fused to CH1 and the other scFv from an anti-IL17 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can bind and inactivate two ligands simultaneously. It is designed for the research of Asthma therapy.